دورية أكاديمية
أعرض في EDS

Impact of SLC22A1 variants rs622342 and rs72552763 on HbA1c and metformin plasmatic concentration levels in patients with type 2 diabetes mellitus.

التفاصيل البيبلوغرافية
العنوان: Impact of SLC22A1 variants rs622342 and rs72552763 on HbA1c and metformin plasmatic concentration levels in patients with type 2 diabetes mellitus.
المؤلفون: Ortega-Ayala A; Department of Pharmacology, Faculty of Medicine, National Autonomous University of Mexico, Mexico City 04510, Mexico., De Andrés F; Department of Analytical Chemistry and Food Technology, Faculty of Pharmacy, University of Castilla-La Mancha, 02071 Albacete, Spain., Llerena A; University Institute for Bio-sanitary Research of Extremadura, 06002 Badajoz, Spain., Bartolo-Montiel CM; Directorate of Planification, Teaching, and Research, High-Speciality Regional Hospital of Ixtapaluca, Ixtapaluca 56530, Mexico., Molina-Guarneros JA; Department of Pharmacology, Faculty of Medicine, National Autonomous University of Mexico, Mexico City 04510, Mexico.
المصدر: Biomedical reports [Biomed Rep] 2024 Jun 17; Vol. 21 (2), pp. 117. Date of Electronic Publication: 2024 Jun 17 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: [Spandidos Publications] Country of Publication: England NLM ID: 101613227 Publication Model: eCollection Cited Medium: Internet ISSN: 2049-9442 (Electronic) Linking ISSN: 20499434 NLM ISO Abbreviation: Biomed Rep Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [London] : [Spandidos Publications], [2013]-
مستخلص: Type 2 diabetes mellitus (T2DM) is a major global health problem. Response to first-line therapy is variable. This is partially due to interindividual variability across those genes codifying transport, metabolising, and drug activation proteins involved in first-line pharmacological treatment. Single nucleotide polymorphisms (SNPs) of genes SLC22A1, SLC22A2 and SLC22A3 affect metformin therapeutic response in patients with T2DM patients. The present study investigated allelic and genotypic frequencies of organic cation (OCT)1, OCT2, and OCT3 polymorphisms among metformin-treated patients with type 2 diabetes mellitus (T2DM). It also reports the association between clinical and genetic variables with glycated haemoglobin (HbA1c) control in 59 patients with T2DM. Patients were genotyped through real-time PCR (TaqMan assays). Metformin plasmatic levels were determined by mass spectrometry. Neither the analysis of HbA1c control by SNPs in SLC22A1 , SLC22A2 and SLC22A3 , nor the dominant genotypic model analysis yielded statistical significance between genotypes in polymorphisms rs72552763 (P=0.467), rs622342 (P=0.221), rs316019 (P=0.220) and rs2076828 (P=0.215). HbA1c levels were different in rs72552763 [GAT/GAT, 6.0 (5.7-6.6), GAT/del=6.5 (6.2-9.0), del/del=6.5 (6.4-6.8); P=0.022] and rs622342 [A/A=6.0 (5.8-6.5), A/C=6.4 (6.1-7.7), C/C=6.8 (6.4-9.3); P=0.009] genotypes. The dominant genotypic model found the lowest HbA1c levels in GAT/GAT (P=0.005) and A/A (P=0.010), in rs72552763 (GAT/GAT vs. GAT/del + del/del) and rs622342 (A/A vs. A/C + CC), respectively. There was a significant correlation between HbA1c levels and metformin dosage amongst del allele carriers in rs72552763 (β 1 =0.14, P<0.001, r 2 =0.387), as opposed to GAT/GAT in rs72552763. There were no differences between HbA1c values in the test set and those predicted by machine learning models employing a simple linear regression based on metformin dosage. Therefore, rs72552763 and rs622342 polymorphisms in SLC22A1 may affect metformin response determined by HbA1c levels in patients with T2DM. The del allele of SNP rs72552763 may serve as a metformin response biomarker.
Competing Interests: The authors declare that they have no competing interests.
(Copyright: © 2024 Ortega-Ayala et al.)
References: Diabetes. 2009 Jun;58(6):1434-9. (PMID: 19336679)
Lancet. 1998 Sep 12;352(9131):837-53. (PMID: 9742976)
Rev Diabet Stud. 2015 Fall-Winter;12(3-4):363-76. (PMID: 27111121)
Pharmaceuticals (Basel). 2022 Jun 22;15(7):. (PMID: 35890074)
Diabetes Care. 2022 Jan 1;45(Suppl 1):S1-S2. (PMID: 34964812)
Curr Drug Metab. 2020;21(4):291-300. (PMID: 32407269)
Salud Publica Mex. 2021 May 03;63(3 May-Jun):444-451. (PMID: 34098602)
Endocr Rev. 2021 Jan 28;42(1):77-96. (PMID: 32897388)
Pharmacogenet Genomics. 2014 Jun;24(6):324-8. (PMID: 24681965)
Diabetes Res Clin Pract. 2022 Jan;183:109119. (PMID: 34879977)
J Clin Pharmacol. 2019 Oct;59(10):1384-1390. (PMID: 31012983)
Eur J Prev Cardiol. 2019 Dec;26(2_suppl):7-14. (PMID: 31766915)
Clin Exp Med. 2015 Nov;15(4):511-7. (PMID: 25492374)
J Clin Invest. 2007 May;117(5):1422-31. (PMID: 17476361)
Genome Med. 2011 Nov 29;3(11):76. (PMID: 22126607)
Pharmacogenet Genomics. 2011 Dec;21(12):837-50. (PMID: 21989078)
Pharm Res. 2007 Jul;24(7):1227-51. (PMID: 17473959)
J Frailty Aging. 2013;2(4):184-91. (PMID: 27070924)
Pharmacogenet Genomics. 2010 Jan;20(1):38-44. (PMID: 19898263)
Diabet Med. 2016 Apr;33(4):511-4. (PMID: 26605869)
فهرسة مساهمة: Keywords: HbA1c; SLC22A1; glycaemic control; metformin; organic cation 1; rs622342; rs72552763
تواريخ الأحداث: Date Created: 20240628 Latest Revision: 20240629
رمز التحديث: 20240629
مُعرف محوري في PubMed: PMC11209864
DOI: 10.3892/br.2024.1806
PMID: 38938740
قاعدة البيانات: MEDLINE
الوصف
تدمد:2049-9442
DOI:10.3892/br.2024.1806